Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases

Abstract

<jats:p>Background: Anemia of Chronic Disease (ACD) can negatively influence the clinical course of Inflammatory Bowel Disease (IBD) patients. The aim of this study was to evaluate the effect of Vedolizumab on ACD in IBD. Methods: Clinical data of 75 IBD patients (25 Crohn’s disease (CD) and 50 Ulcerative Colitis (UC)) receiving Vedolizumab in a tertiary referral IBD center were retrospectively evaluated and the effect of the drug on ACD was ascertained at weeks 14 and 24. Results: ACD was diagnosed in 35 (11 CD and 24 UC) out of 75 (47%) IBD patients. At both week 14 and week 24, improvements and resolutions of ACD were achieved by 13/35 (37%) and 11/35 (31%) patients, respectively. Baseline demographic/clinical characteristics did not differ between patients with ACD improvements/resolutions and those with persistent ACD. Clinical response occurred more frequently in patients who achieved ACD resolution (10/11, 91%) than in those without ACD improvement (5/11, 45%, p = 0.022). When analysis was restricted to anemic patients, ACD resolution was documented in 10/22 patients (45%) achieving clinical response and 1/13 of non-responders (8%; p = 0.02). Conclusions: ACD occurs in half of the IBD patients and, in nearly two thirds of them, Vedolizumab treatment associates with ACD resolution/improvement.</jats:p>

Real-life effectiveness and safety of vedolizumab in moderate-to-severe ulcerative colitis: A single-center experience in Northern China

“…Clinical responses were achieved in 91% of patients who had anemia correction but in only 45% of patients whose anemia did not improve. Given that Scarozza et al [41] have demonstrated a positive effect of VDZ in UC patients with anemia, our analysis focuses more on the correlation between hemoglobin and LOR during the maintenance phase of VDZ. We found that 2-thirds of UC patients with hemoglobin < 120 g/L at baseline developed LOR after VDZ induction therapy, which was significantly higher than in patients with baseline hemoglobin ≥ 120 g/L.…”

“…Previous studies have confirmed that inflammatory anemia negatively affects the prognosis of treatment for patients with IBD. [40] In a retrospective study of 35 of 75 IBD patients with anemia, Scarozza et al [41] found a strong correlation between correction of anemia and clinical response to VDZ. Clinical responses were achieved in 91% of patients who had anemia correction but in only 45% of patients whose anemia did not improve.…”

Anemia of chronic diseases: current state of the problem and perspectives

“…При проведении субанализа результатов исследования CANTOS, в котором изучалась эффективность канакинумаба (моноклональное антитело к ИЛ-1β) у пациентов, перенесших инфаркт миокарда и имеющих признаки системного воспаления (повышенный уровень С-реактивного белка), оказалось, что терапия канакинумабом у пациентов с изначально нормальным уровнем гемоглобина снижает риск развития анемии, а у пациентов с изначально сниженным уровнем гемоглобина приводит к достоверно большему его приросту по сравнению с плацебо [37]. Эффективность в отношении АХЗ у пациентов с воспалительными заболеваниями кишечника продемонстрирована для ведолизумаба [38]. Способность снижать уровень гепсидина и повышать уровень эритроферрина и эритропоэтина обнаружена у дапаглифлозина [39], хотя прежде считалось, что способность препаратов из класса ингибиторов натрий-глюкозного котранспортера 2-го типа повышать уровень гемоглобина связана в первую очередь с их диуретическим действием.…”

Trends in the Comprehension and Management of Gastrointestinal Tract Disorders

“…Inflammatory bowel diseases (IBD) represent another prime example that highlights therapeutic improvements of GI tract disorders. The introduction, in the clinical setting, of biologic drugs has allowed the management of IBD patients to become optimized for steroid-refractory or steroid-resistant diseases [ 11 ], improving not only the mucosal state (with a mucosal remission) but also the clinical consequences of this inflammation [ 12 ]. These advances have allow us to focus on the endpoint beyond the clinical and endoscopic parameters, including the patient’s quality of life [ 13 ].…”